VPRIV® (velaglucerase alfa) for injection is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.

Support Programs

When you're prescribed VPRIV, and throughout your journey, you will be supported all the way. For OnePath® patients, Takeda offers a range of support to help answer questions.

OnePath logo

Meet the OnePath Support Team

Patient Support Manager (PSM) blue logo

Patient Support Manager (PSM)

When you enroll in OnePath, your dedicated Patient Support Manager (PSM) will be your primary contact and can help with many aspects of your treatment with VPRIV. This includes helping to navigate insurance coverage, providing information on financial assistance options, work with your site of care, and providing you with additional resources.

Patient Access Manager (PAM) blue logo

Patient Access Manager (PAM)

Your Patient Access Manager (PAM) can help to assist with any potential insurance or coverage issues. Your PAM can serve as a resource for complex reimbursement, financial, or other access-related issues.

If English is not your preferred language, let your Patient Service Manager know. The team can communicate with you over the phone using a translation service in a variety of languages, including Spanish, Yiddish, and more.

Joyce and Laura, OnePath patient support managers.
Support Programs Bubble Images

To learn more about the team, contact OnePath® online at OnePath.com or speak to one of our OnePath® Patient Support Managers, available from 8:30am to 8:00pm (ET) at 1-866-888-0660.

OnePath ® Product Support

OnePath® is a no-cost program to help you every step of the way. OnePath® provides personalized product support for those who have been prescribed VPRIV for the approved indication to get access to their medicine, in addition to providing other product support services, such as:

Blue dollar symbol icon

Financial Assistance Options

Copay assistance for those who are eligible*, as well as assistance with navigating insurance coverage.

Blue calendar icon

Coordinate with Site of Care

Help to coordinate between your specialty pharmacy and site of care for you or your loved one. Traveling or moving? We can help with access to VPRIV during that too.

Blue ipad icon

Resources and Education

Guidance on educational materials and resources, including the no-cost OnePath® mobile app.

Download the OnePath® Patient App to your mobile device from the App Store or Google Play.

Blue icon with house and two arrows pointing left and right

Assistance During Life Transitions

Provide information on what you can expect as you continue to manage your treatment when things change, including if you are moving home, moving to college, or changing jobs.

* To be eligible, you must be enrolled in OnePath and have commercial insurance. Other terms and conditions apply. Call OnePath for more details.

You can visit OnePath.com or speak to our OnePath® Patient Support Managers, available from 8:30am to 8:00pm (ET) at 1-866-888-0660, to learn more.

Bubble Top Left
QuickStart logo

QuickStart can help streamline your VPRIV treatment initiation.

When starting VPRIV—whether you’re new to enzyme replacement therapy (ERT) or just switching from another treatment—there may be some administrative hurdles with insurance. One of the most commonly encountered issues that has the potential to delay the start of your treatment is called a prior authorization (PA).

A prior authorization is when your insurance company requires your doctor to fill out some additional paperwork before your prescription is processed. This can delay you from starting treatment while your paperwork is being evaluated and processed.

QuickStart allows eligible patients to receive their infusion while the prior authorization is still being reviewed. You could receive up to two free doses of VPRIV, if eligible and prescribed by your doctor.

Fill in a QuickStart Form with your doctor or visit OnePath.com to learn more. If you are enrolled in OnePath®, your Patient Support Manager can help answer questions you may have on the QuickStart program.*

*Additional terms and conditions apply.

Bubble Bottom Right
PreppedAhead program icon

What many patients don’t always expect when starting an ERT is that in addition to infusion time, there is usually some time associated with a site of care’s infusion preparation.

PreppedAhead™ is a program that provides you with the option of having your site of care prepare your treatment before you arrive—so you don’t have to wait as long before your infusion begins.

This service is only available to patients enrolled in OnePath® at sites of care that are enrolled in the PreppedAhead™ program. Talk to your OnePath® Patient Support Manager about PreppedAhead™ today.

important safety information <

Hypersensitivity reactions, including serious allergic reactions (anaphylaxis), have occurred. VPRIV should be administered under the supervision of a healthcare professional.

important safety information <

Hypersensitivity reactions, including serious allergic reactions (anaphylaxis) have occurred. VPRIV should be administered under the supervision of a healthcare professional. VPRIV is given every other week by intravenous infusion that typically takes up to 60 minutes. Appropriate medical support should be available when VPRIV is administered. The most serious side effects in patients treated with VPRIV were hypersensitivity reactions.

Hypersensitivity reactions were the most commonly observed side effects in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of hypersensitivity reactions were: headache, dizziness, low blood pressure, high blood pressure, nausea, tiredness/weakness, and fever. Hypersensitivity reactions in the clinical trials include any event considered related to and occurring within up to 24 hours of VPRIV infusion, including one case of anaphylaxis. Generally the reactions were mild and, in patients not previously treated, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. After the drug was approved, additional hypersensitivity reactions of chest discomfort, difficulty breathing, itching and vomiting have been reported. In some cases, vomiting can be serious and require hospitalization and/or stopping the medication.

If anaphylactic or other acute reactions occur, your healthcare provider will immediately discontinue the infusion of VPRIV and initiate the appropriate medical treatment. A hypersensitivity reaction should be treated based on the severity of the reaction. Your healthcare provider may manage a reaction by slowing the infusion rate or treating with medicine such as antihistamines, fever-reducing agents and/or corticosteroids or possibly stopping the medication and then restarting with a longer infusion time. For patients who have had symptoms of hypersensitivity reaction to enzyme replacement therapy, the doctor may consider treating the patient with antihistamines and/or corticosteroids before an infusion to help prevent such a reaction from happening.

The most commonly reported side effects during clinical studies (in ≥10% of patients) were hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, increased time it takes for blood to clot, tiredness/weakness, and fever. In clinical studies, the overall frequency of side effects was generally higher in the patients not previously treated with ERT than in the patients who switched from imiglucerase to VPRIV.

Talk to your doctor if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

The safety and efficacy profiles were similar in pediatric (ages 4 to 17) and adult patients. The safety of VPRIV has not been established in patients under 4 years of age. Side effects more commonly seen in pediatric patients compared to adult patients include (>10% difference): rash, increased time it takes for blood to clot, and fever.

The side effect profile in elderly patients was generally similar to that seen in pediatric and other adult patients. In general, dose selection for an elderly patient should be approached cautiously, considering other existing medical conditions.

As with all therapeutic proteins, there is a potential for developing antibodies to VPRIV. In clinical studies, 1 of 54 (2%) patients who had not previously been treated with ERT, who were then treated with VPRIV, developed antibodies. One additional patient developed antibodies to VPRIV during an extension study.  It is unknown if having antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.

For additional safety information, please click here for Full Prescribing Information and discuss with your doctor
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, contact Takeda at 1-877-TAKEDA-7 (1-877-825-3327), or by email at medinfous@takeda.com